{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"258.26","value":"-66.50"},{"groupId":"OG001","spread":"158.23","value":"-77.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Change from Baseline in Biochemical Bone Markers: CTX-I was assessed","dispersionType":"Standard Deviation","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEAN","populationDescription":"FAS was used for analysis. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure and n=number pf participants analysed for this outcome measure at specific time point. Missing data was imputed by last observation carried forward (LOCF) method.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Change From Baseline in Biochemical Bone Markers: Carboxyterminal Collagen Crosslinks (CTX-I)","type":"SECONDARY","unitOfMeasure":"Nanogram per liter"}